Sign up
BNBX

Applied DNA Sciences, Inc. (NASDAQ: BNBX)

Financial Services · Asset Management

——

Quote unavailable · The latest market session has not been published.

Set alert

The Quantellect read. The borrow fee is 50.18%. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.2× vs peer median 5.5×

MomentumOversold

RSI (14) 26.3 (overbought above 70, oversold below 30)

Trend—

—

Short interest0.1% of float

FINRA settlement Oct 30, 2026

BNBX price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

BNBX · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

—/100—

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Not scored: Equity peers

LiquidityNot scoredShortNot scoredSqueezeNot scoredTrendNot scoredMomentumNot scoredValuationNot scoredStabilityNot scored
What each one means
  • LiquidityNot scored

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • ShortNot scored

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • SqueezeNot scored

    Higher scores reflect a higher published Squeeze score within equity peers.

  • TrendNot scored

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • MomentumNot scored

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • ValuationNot scored

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • StabilityNot scored

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

— · Quantellect signals not available

How BNBX compares with its industry

Against 219 other US-listed Asset Management stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Latest-quarter year-over-year sales growth was 98.9%, higher than 97% of 219 peers.Peer median 0.0% · As of Nov 17, 2026

Points of caution

  1. Six-month return was -89.6%, with only 0% of 216 peers reporting a lower value.Peer median −5.1% · As of Nov 15, 2026
  2. Trailing-year return on equity was -439.5%, with only 2% of 214 peers reporting a lower value.Peer median 3.5% · As of Nov 17, 2026
  3. Trailing-year net margin was 0%, with only 16% of 189 peers reporting a lower value.Peer median 8.7% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.23×5.50×
    Lowest 10%

    Higher than 2% of 212 peers

  • Forward P/E158.73×9.43×

    Not ranked: only 104 of 219 peers report it

  • Price/book0.06×0.89×
    Lowest 10%

    Higher than 1% of 212 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin59.4%100.0%

    Higher than 20% of 173 peers

  • Operating margin—56.9%

    Not ranked: only 208 of 219 peers report it

  • Net margin0.0%8.7%

    Higher than 16% of 189 peers

  • Return on equity−439.5%3.5%
    Bottom 10% of peers

    Higher than 2% of 214 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year98.9%0.0%
    Top 10% of peers

    Higher than 97% of 219 peers

  • 5-year sales growth rate—5.9%

    Not ranked: only 35 of 219 peers report it

Balance sheet

Not enough peers report balance sheet metrics for a group comparison.

  • Current ratio5.794.46

    Not ranked: only 19 of 219 peers report it

  • Debt/equity (total borrowings)—1.10

    Not ranked: only 62 of 219 peers report it

Momentum

Returns are lower than most peers.

  • 1-year return—−6.1%

    Not ranked: only 211 of 219 peers report it

  • 6-month return−89.6%−5.1%
    Lowest of 216 peers

    Higher than 0% of 216 peers

  • 3-month return−80.2%−8.5%
    Lowest of 216 peers

    Higher than 0% of 216 peers

Compared with 219 other US-listed Asset Management stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 12, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026—−$0.57—
Q2 2026—−$0.68—
Q1 2025—−$2.08—
Q3 2025—−$34.00—
Q2 2025—−$15.35—
Q1 2024−$0.31−$0.56—
Annual 2024—−$1.82—
Q3 2024−$262.50$0.47—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FCITADEL ADVISORS LLCOpened position$39.6K13F filing
All smart-money activity →

News and press releases

All BNBX news →

Company profile

BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic

CEO
Mr. Clay D. Shorrock Esq., J.D.
Headquarters
Stony Brook, NY, United States
Employees
26
IPO date
Jul 15, 2003
Sector
Financial Services
Industry
Asset Management
Website
bnbx.io

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.